Motley Fool2d agobullish
Is Kailera Therapeutics a Buy After Its Sizzling IPO?There's a new challenger to the more established players in the weight-loss drug space.
Noticias
Solo titulares de alta señal — eventos macro, earnings, M&A, regulación. Listicles y clickbait de analistas filtrados por defecto. Refrescado cada hora.
147last 24h
1629last 7d
293🟢 bullish (7d)
172🔴 bearish (7d)
138publishers
Investor's Business Daily6d agoneutral
Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In ObesityAnalysts initiated covered Tuesday of IPO stock Kailera Therapeutics, a potential competitor to Lilly and Novo in obesity treatment.